A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 30 May 2018

At a glance

  • Drugs Alogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Acronyms EXAMINE
  • Sponsors Takeda; Takeda Global Research and Development Center
  • Most Recent Events

    • 30 May 2018 Results assessing the prognostic implications of changes in N-terminal B-type natriuretic peptide (NT-proBNP) concentration in patients with T2DM and ischemic heart disease (n=5224) published in the Diabetes Care
    • 13 Apr 2018 Results assessing cardiovascular outcomes following treatment with alogliptin, published in the Clinical Cardiology.
    • 23 Mar 2018 Results (n=1398) published in the American Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top